Related Experiment Video
Updated: Dec 15, 2025
12:36
Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
Published on: March 14, 2020
17.2K
A Selective PPARγ Modulator Reduces Hepatic Fibrosis.
Benita L McVicker1,2, Frederick G Hamel1,2,3, Ronda L Simpson1,2
1Research Service, VA Nebraska-Western Iowa Health Care System, Omaha, NE 68105, USA.
Biology
|July 8, 2020
Summary
Selective PPARγ modulators show promise for treating liver fibrosis. SR1664 effectively reduced established hepatic fibrosis and activated hepatic stellate cells without adverse effects, suggesting a new therapeutic avenue.
Area of Science:
- Hepatology
- Pharmacology
- Fibrosis Research
Background:
- Hepatic fibrosis, driven by chronic liver injury, leads to severe liver damage, including cirrhosis and cancer.
- Thiazolidinediones target peroxisome proliferator-activated receptor γ (PPARγ) and show antifibrotic effects but have limitations.
- Established fibrosis treatment remains challenging due to drug side effects and limited efficacy.
Purpose of the Study:
- To evaluate the efficacy of SR1664, a selective PPARγ modulator, in established hepatic fibrosis.
- To assess SR1664's impact on collagen deposition and hepatic stellate cell activation.
- To determine if SR1664 causes weight gain or adiposity.
Main Methods:
- Utilized a carbon tetrachloride-induced mouse model of established hepatic fibrosis.
- Administered SR1664 and monitored collagen content and hepatic stellate cell activation.
- Assessed changes in body weight and adiposity.
Main Results:
- SR1664 significantly reduced total and type 1 collagen in fibrotic livers.
- The drug decreased the abundance of activated hepatic stellate cells.
- SR1664 treatment did not increase body weight or adiposity.
Conclusions:
- Selective PPARγ modulation with SR1664 is effective against established hepatic fibrosis.
- SR1664 ameliorates the profibrotic phenotype of hepatic stellate cells.
- SR1664 represents a potential novel therapeutic strategy for liver fibrosis.
